The strategy of surgical treatment and targeted therapy in gastrointestinal stromal tumors        SHI Ying-qiang. Department of Abdominal Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China
Abstract    It is well known that imatinib, as a targeted drug, has converted the therapy strategy of GIST patients. However, currently, the usage of imatinib has changed from the mode of merely drug therapy to the style of combining drug therapy and surgical treatment. The results of PET-CT imaging are in accord with symptomatic relief of GIST patients, which suggests that PET-CT imaging can be used in assessing the healing efficacy at the early stage of treatment. Dynamic enhanced ultrasonic contrast has become a new function imaging for evaluating the effect of targeted therapy in GIST patients. As for high risk GIST patients, imatinib , as an adjuvant therapy, should be used for 1 to 2 years. Neoadjuvant therapy has been widely accepted. Currently, with regards to patients with imatinib resistence, sunitinib could be adopted for GIST patients.